Market Data 
Markets
Replies to post #249972 on Biotech Values
However, other aspects of Altimmune’s safety data look weak compared to Wegovy and Zepbound. The rates of drug-related adverse events leading to discontinuation were 16.2% and 15.5% in the two top dose cohorts of the pemvidutide trial. Across both Zepbound trials, the rate was 6.7% at the top dose. The rate for Wegovy was 6.8%.
Nausea was more common in the pemvidutide study too, particularly compared to Zepbound. At the two highest pemvidutide doses, 59% and 50% of patients reported nausea. That compares to a maximum rate of 29% for Zepbound and 44% for Wegovy. Lilly and Novo titrated the dose, and allowed dose reduction, in their phase 3 trials.
There was no dose titration at the two lower pemvidutide doses, only a four-week titration at the top dose and no option for patients who experienced tolerability problems to drop down to a lower dose. On a call to discuss the latest data, Harris said that “by allowing dose reduction in the phase 3 program, we expect the discontinuation rates to drop down to single digits as they have in other phase 3 programs.”
AI
